Business

European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai

The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."

adminadmin
Jul 26, 2024 - 20:00
 0  3
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
Read More

Tags:

Previous Article

Paris Olympics is the latest test of whether sports can win subscribers for NBC'...

Next Article

LVMH CEO Bernard Arnault says Olympics sponsorship honors the spirit of France

admin
admin

Related Posts

A look inside a $60 million Florida mansion with subterranean secrets and Italian flair

A look inside a $60 million Florida mansion with subter...

admin Jul 13, 2024  0  44

Sony Pictures is buying Alamo Drafthouse theater chain

Sony Pictures is buying Alamo Drafthouse theater chain

admin Jun 13, 2024  0  6

Stocks making the biggest moves midday: Boeing, Vistra, Match Group and more

Stocks making the biggest moves midday: Boeing, Vistra,...

admin Aug 1, 2024  0  4